Meet the challenge of changing stakeholder demands and increasing cost constraints with IQVIA's integrated technology services and analytics-driven offerings.
While the nation’s primary healthcare focus remains on the COVID-19 pandemic as we move through the third year of its disruptive effects and the death toll approaches 1 million, other important dynamics are playing out with respect to the utilization of health services, the use of prescription medicines, and the associated spending levels, including patient out-of-pocket costs. Understanding these elements of the health system and how they may evolve over the next five years remains critical to decision-makers and stakeholders – including patients.
This annual trend report - The Use of Medicines in the U.S. 2022 – is intended to provide a grounding in relevant information across a range of issues with both short- and long-term implications. It includes the Health Services Utilization Index, which tracks a range of healthcare activities that affect the use of medicines.
Spending and growth drivers reflect the significant differences in levels of spending by stakeholders as discounts and rebates distort these trends even as the most impactful driver has been the amount spent on COVID-19 vaccines and therapeutics. An overview of patient out-of-pocket costs shows that while most patients’ costs are falling, a small proportion have high costs which impact their use of medicines with implications for their health outcomes.
The outlook for the years ahead includes the expected end of the pandemic as well as significant shifts in drivers of usage and spending overall and in key therapy areas.
The Quest for Evidence-Based Research in Healthcare Decision-making.
Meet the challenge of changing stakeholder demands and increasing cost constraints with IQVIA's integrated technology services and analytics-driven offerings.